Incyte Corporation (INCY) - Quarterly EPS earnings growth

Official company branding of Incyte (INCY)

Quarterly EPS dynamics demonstrate current profitability trends, where the value of -282.60 expresses the metric level. Incyte Corporation (INCY) is a biopharmaceutical leader protected by Jakafi patents and focused on high-margin hematology. Revenues are based on the commercialization of targeted therapies for autoimmune and oncological pathologies. The business is currently plateauing, diversifying its portfolio with new developments ahead of patent expirations.

Incyte (INCY) Earnings per share growth in annualized terms for the last twelve months: for the period 07/04/2022 - 11/15/2026

Analytical breakdowns for Incyte Corporation

- market value and analyst target forecast:
Price Chart Incyte Corporation|INCY - Broker Consensus Forecast
- market capitalization indicators:
Market Capitalization Incyte Corporation|INCY - Real Price to Acquire Entire Company
- balance sheet net asset value indicators:
Net Assets per Single Share Incyte|INCY - Total Stockholders' Equity|Market Value to Book Value Ratio incyte.com|INCY - Aggregate Company Assets
- debt and liquidity details:
Debt to Equity Incyte Corporation|INCY - Long-Term Liabilities to Capital|Short-Term Debt to Capital incyte.com|INCY - Company Total Indebtedness|Debt to Book Value Incyte Corp.|INCY - Long-Term Debt|Company Current Liabilities Incyte|Quick Liquidity Indicator incyte.com
- earnings and market multiples details:
INCY - Profit After Payment of Taxes|Projected Future Earnings Incyte Corporation|INCY - Company Value to Net Income|Forward P/E Multiple Incyte Corp|INCY - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Incyte Corporation|INCY - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Incyte|INCY - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months incyte.com|INCY - Earnings per share trend in current year|Expected earnings per share growth for next year Incyte Corporation
- sales volume and revenue indicators:
INCY - Company Total Revenue|Projected Sales Volume Incyte Pharma|INCY - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio Incyte Corp|INCY - Sales Growth YoY (Last 12 Months)
Fundamental company analysis:incyte.com, INCY
Manufactured product of Incyte Pharma

Quarterly EPS growth measures the percentage change in net income per share compared to the same period last year. Positive momentum confirms the effectiveness of business scaling and the growth of the asset's fundamental value. By analyzing the growth rates of quarterly net income per share, an investor assesses the risk of overpaying for the asset. For Incyte Corporation (INCY), this indicator reflects the current dependence on Jakafi sales. Stability in this metric will prove management's ability to successfully diversify the drug portfolio.

Analysis of competing companies

HCM: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months NUVB|DAWN (dayonebio.com) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months monopartx.com (MNPR)|Year-over-year earnings per share growth for the last twelve months Inhibrx Corp (INBX)|IMAB - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Fennec Pharmaceuticals Inc FENC|Heron Therapeutics - Year-over-year earnings per share growth for the last twelve months|NVCT - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months coherus.com|CRBP: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Cardiff Oncology, Inc. CRDF|Year-over-year net earnings per share growth for the last 12 months BYSI|Earnings per share growth in annualized terms for the last twelve months BioAtla BCAB|Year-over-year net earnings per share growth for the last 12 months LIXT (Lixte Biotechnology)|CTXR (Citius Pharma) - Year-over-year earnings per one share growth for the last 12 months|Cellectar Biosciences - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months BLRX (BioLineRx)|Can-Fite BioPharma, Ltd. - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (aprea.com)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion (SLXN)|Year-over-year earnings per share growth for the last twelve months nucana.com|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth G1 Therapeutics Inc. (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Therapeutics, Inc.) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months Portage Biotech Inc